Abstract
Severe pneumonia (SP) is associated with high mortality and morbidity and increased antibiotics resistance in the past decades further deteriorate its prognosis. Xuebijing, a Chinese medicine extract infusion formula, which has been in market since 2004 for sepsis treatment, has shown significant effects on cytokine reduction, anti-coagulation, and neutralization of released bacteria cytotoxins in various infectious disease including pneumonia. To confirm the previous findings, a multiple center, randomized clinical trial has been conducted in 31 tertiary hospitals in China since Jun 2013 to Apr 2016 after approval from IRB. A total of 710 SP patients who met criteria of SP based on 2007 ATS/IDSA guideline were enrolled into the study after consent (with registration at clinical trials website, number : ChiCTR-TRC-13003534 ). They were assigned into two arms after central randomization, one arm as control, and one arm with Xuebijing injection (100 ml twice daily) for 5-7 days. Clinical and laboratory parameters were recorded and analyzed for efficacy and safety. Results showed Xuebijing infusion significantly reduced mortality (24.63% vs 15.87% in control and treatment group separately, P
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
